Flumequine

氟甲喹
分子式:C14H12FNO3    分子量:261.25

产品描述

Flumequine是一种人工合成的抗生素,在旋转酶/拓扑异构酶水平影响哺乳动物细胞染色体和DNA解旋。

靶点

Topoisomerase II

         

IC50

15 μM

         

体外研究

Flumequine inhibits eukaryotic topoisomerase II, which is responsible for the double-strand DNA breakage reaction as well as bacterial gyrase, inhibitory effects of FL on topoisomerase II are high relative to the influence on bacterial gyrase. Flumequine has minimum inhibitory concentration (MIC) ranging from 0.06 μg/mL to 32 μg/mL in 12 clinical A. salmonicida isolates. Flumequine enhibits high E(max) values of 16 for the most resistant isolates, which indicates an important contribution of efflux to the resistance phenotype. Flumequine accumulation experiments confirmes that high E(max) values are associated with a much lower level of accumulation.

体内研究

Flumequine (4000 ppm, oral diet) induces dose-dependent DNA damage in the stomach, colon, and urinary bladder of adult mice at 3 hours but not at 24 hours after its administration.Flumequine shows the bioavailability of 44.7% following oral administration of medicated feed in Atlantic salmon. Flumequine results in the volumes of distribution at steady state of 3.5 L/kg, elimination half-life (t 1/2) of 22.8 hours and area under plasma drug concentration-time curve (AUC) of 140 μg×hours/mL following intravenous administration in Atlantic salmon. Flumequine (100 mg/L) reduces the mean length of root, hypocotyle, cotyledon and the mean number of secondary roots in aquatic weed Lythrum salicaria L. Flumequine (10 mg/kg, oral) results in the volumes of distribution at steady-state (Vss) of 2.41 L/kg (cod) and 2.15 L/kg (wrasse) following intravenous administration. Total body clearances (Cl) are 0.024 L/h.kg (cod) and 0.14 L/h.kg (wrasse) and the elimination half-lives (t1/2 λ z) are calculated to be 75 hours (cod) and 31 hours (wrasse) after Flumequine (10 mg/kg, oral) administration. The oral bioavailabilities (F) are calculated to be 65% (cod) and 41% (wrasse) following oral administration of Flumequine.

溶解性

DMSO 3 mg/mL,水 <1 mg/mL,乙醇 <1 mg/mL

稳定性

2年 -20°C粉状,6月-80°C溶于DMSO

特征

           

运输条件:2~8℃运输

我司所售出产品仅供于科研研究用途(非临床科研研究),每次销售产品行为都适用于我司网上所列明的

CAS 号:42835-25-6
英文名字:氟甲喹
质量标准:>98%,BR,进分
分子式:C14H12FNO3 

Flunarizine Hydrochloride

Flunarizine Hydrochloride;盐酸氟桂利嗪
分子式:C26H26F2N2.2(HCl)    分子量:477.42

简介: 盐酸氟桂利嗪  Flunarizine是钙离子通道阻断剂。
别名:Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenyl-2-propen-1-yl]-, hydrochloride (1:2)
物理性状及指标:
外观:………………白色至类白色固体
溶解性:……………DMSO 5 mg/mL (10.47 mM);Water Insoluble;Ethanol 3 mg/mL (6.28 mM)
含量:………………>99%

储存条件: 常温,避光防潮密闭干燥 

运输条件:常温运输
生物活性
氟桂利嗪是一种选择性钙离子阻滞剂,是一种被归类为钙通道阻滞剂的药物。氟桂利嗪是一种非选择性钙入口阻滞剂,具有组胺H 1受体阻断活性。对预防偏头痛、闭塞性外周血管病、中枢性和外周性眩晕有效,对癫痫的治疗有辅助作用。它可能有助于减少与更严重形式的交替性偏瘫相关的瘫痪发作的严重程度和持续时间,并对快速发作的肌张力障碍性帕金森病(RDP)有效。

相关产品推荐(更多相关靶点抑制剂请详询官网或客服)

MB8069-S

盐酸氟桂利嗪(标准品)

用途及描述 :科研试剂,广泛应用于分子生物学,药理学等科研方面,严禁用于人体。盐酸氟桂利嗪  Flunarizine是钙离子通道阻断剂,本品可用于相关领域的科研实验。
储液配置

Flunarizine Hydrochloride

1 mg

5 mg

10 mg

1 mM

2.0946 mL

10.4730 mL

20.9459 mL

5 mM

0.4189 mL

2.0946 mL

4.1892 mL

10 mM

0.2095 mL

1.0473 mL

2.0946 mL

50 mM

【注意】
●我司产品为非无菌包装,若用于细胞培养,请提前做预处理,除去热原细菌,否则会导致染菌。

●部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,以上数据仅供参考交流研究之用。

我司所售出产品仅供于科研研究用途(非临床科研研究),每次销售产品行为都适用于我司网上所列明的

CAS 号:30484-77-6
英文名字:Flunarizine Hydrochloride
质量标准:>99%,BR
分子式:C26H26F2N2.2(HCl)